Tonix Pharmaceuticals Holding Corp. 8-K

What Happened
On March 26, 2026, Tonix Pharmaceuticals Holding Corp. (TNXP) announced it dosed the first participant in an investigator-initiated Phase 1 study evaluating TNX-1900 (intranasal potentiated oxytocin). The study, led by Dr. Antoinette Maassen van den Brink, Professor of Neurovascular Pharmacology at Erasmus University Medical Center, will assess trigeminal nerve–mediated vasodilation of the forehead using capsaicin and electrical stimulation as a model of trigeminal neurovascular reactivity in healthy female volunteers.

Key Details

• Date filed/announced: March 26, 2026.
• Product candidate: TNX-1900 (intranasal potentiated oxytocin).
• Study type: Investigator-initiated Phase 1 clinical study in healthy female volunteers using capsaicin and electrical stimulation to model trigeminal neurovascular reactivity.
• Principal investigator/collaborator: Dr. Antoinette Maassen van den Brink, Erasmus University Medical Center.
• Company disclosure: Press release dated March 26, 2026 filed as Exhibit 99.01 to the 8-K.

Why It Matters
This dosing milestone marks early human testing of TNX-1900 and represents clinical progress for Tonix’s intranasal oxytocin program. Results from this Phase 1 study will provide initial human safety and pharmacodynamic information about the candidate’s effects on trigeminal neurovascular responses—data that can inform future trial design and development decisions. The filing does not include efficacy or financial results; further data and subsequent trial milestones will be required to assess clinical value and potential commercial impact.